Valuation: Northwest Biotherapeutics, Inc.

Market Cap 32Cr 28Cr 26Cr 24Cr 45Cr 3.1TCr 46Cr 308.22Cr 120.51Cr 1.55TCr 121.69Cr 119.05Cr 5.16TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 42Cr 36Cr 34Cr 31Cr 58Cr 4.02TCr 59Cr 399.59Cr 156.23Cr 2.01TCr 157.76Cr 154.34Cr 6.69TCr EV / Sales 2026 *
-
EV / Sales 2027 * 11.5x
Free-Float
95.3%
Yield 2026 *
-
Yield 2027 * -
15/08 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06/08 Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration CI
09/07 Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma CI
16/05 Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
21/04 Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic CI
16/04 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
15/04 Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
15/11 Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
14/11 Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP CI
31/25/31 Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC CI
27/25/27 Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding CI
24/25/24 Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC. CI
27/25/27 Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million. CI
1 day+0.49%
1 week+11.66%
Current month+25.00%
1 month+23.87%
3 months-18.81%
6 months-14.58%
Current year-10.38%
1 week 0.18
Extreme 0.184
0.21
1 month 0.14
Extreme 0.1416
0.21
Current year 0.14
Extreme 0.1411
0.34
1 year 0.14
Extreme 0.1411
0.37
3 years 0.14
Extreme 0.1411
1.09
5 years 0.14
Extreme 0.1411
2.05
10 years 0.14
Extreme 0.14
2.51
Manager TitleAgeSince
Chief Executive Officer 82 01/06/2007
Chief Executive Officer 71 08/06/2011
Chief Tech/Sci/R&D Officer 67 01/01/2000
Director TitleAgeSince
Director/Board Member 82 01/01/1998
Chairman 71 17/05/2007
Director/Board Member 57 01/04/2012
Date Insider Type Main position Quantity % Market Cap.
29/08/24 Don

Founder

10,00,000 0.0826%
09/08/24 Don

Chief Technology Officer

30,00,000 0.2478%
08/08/24 Don

Founder

10,00,000 0.0826%
Change 5-day change 1-year change 3-year change Capi.($)
+0.49%+11.66%-16.33%-58.43% 32Cr
-1.90%+2.85%+62.82%+104.13% 7.01TCr
-3.21%-4.32%+31.85%+57.27% 5.29TCr
-2.05%-5.61%-3.18%+449.71% 2.7TCr
-1.27%-1.57%+45.90%+8.25% 2.36TCr
+1.05%-0.62%-18.00%-11.93% 2.34TCr
+3.81%+20.97%+266.37%+531.28% 1.94TCr
+0.10%+1.40%+35.36%-19.94% 1.87TCr
-0.95%-3.52%+19.93%+594.00% 1.59TCr
+1.24%-5.23%+33.75%+137.66% 1.27TCr
Average -0.27%+1.75%+45.85%+179.20% 2.64TCr
Weighted average by Cap. -1.09%+0.55%+50.15%+164.72%

Financials

2026 *2027 *
Net sales - 3.89Cr 3.36Cr 3.16Cr 2.87Cr 5.4Cr 372.3Cr 5.49Cr 37Cr 14Cr 186.43Cr 15Cr 14Cr 619.55Cr
Net income - -
Net Debt 9.61Cr 8.3Cr 7.8Cr 7.09Cr 13Cr 918.73Cr 14Cr 91Cr 36Cr 460.07Cr 36Cr 35Cr 1.53TCr 12Cr 11Cr 10Cr 9.22Cr 17Cr 1.19TCr 18Cr 118.81Cr 46Cr 598.26Cr 47Cr 46Cr 1.99TCr
Logo Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.
Employees
105
Date Price Change Volume
14/26/14 $0.1920 +1.05% 14,31,468
13/26/13 $0.1900 +0.64% 14,89,846
12/26/12 $0.1888 -0.63% 26,90,638
11/26/11 $0.1900 +2.15% 26,18,541
10/26/10 $0.1860 +1.31% 26,18,804
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1920USD
Average target price
1.000USD
Spread / Average Target
+420.83%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NWBO Stock